Is Mangoceuticals, Common Stock a Good Investment?
Mangoceuticals, Common Investment Advice | MGRX |
- Examine Mangoceuticals, Common's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Mangoceuticals, Common's leadership team and their track record. Good management can help Mangoceuticals, Common navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Mangoceuticals, Common's business and its evolving consumer preferences.
- Compare Mangoceuticals, Common's performance and market position to its competitors. Analyze how Mangoceuticals, Common is positioned in terms of product offerings, innovation, and market share.
- Check if Mangoceuticals, Common pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Mangoceuticals, Common's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Mangoceuticals, Common Stock stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Mangoceuticals, Common Stock is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Sell | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Mangoceuticals, Common Stock
Researching Mangoceuticals, Common's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 37.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.46. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mangoceuticals, Common recorded a loss per share of 5.7. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 16th of October 2024.
To determine if Mangoceuticals, Common is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mangoceuticals, Common's research are outlined below:
| Mangoceuticals, Common generated a negative expected return over the last 90 days | |
| Mangoceuticals, Common has high historical volatility and very poor performance | |
| Mangoceuticals, Common has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 731.49 K. Net Loss for the year was (9.21 M) with profit before overhead, payroll, taxes, and interest of 4.85 K. | |
| Mangoceuticals, Common generates negative cash flow from operations | |
| About 37.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Eugene Johnston of 25000 shares of Mangoceuticals, Common subject to Rule 16b-3 |
Mangoceuticals, Common Quarterly Cash And Short Term Investments |
|
Mangoceuticals, Common uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mangoceuticals, Common Stock. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mangoceuticals, Common's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of January 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Mangoceuticals, Common's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.18 M.Market Cap |
|
Mangoceuticals, Common's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (8.77) | (8.33) | |
| Return On Capital Employed | (10.98) | (10.43) | |
| Return On Assets | (8.77) | (8.33) | |
| Return On Equity | (11.89) | (11.30) |
Determining Mangoceuticals, Common's profitability involves analyzing its financial statements and using various financial metrics to determine if Mangoceuticals, Common is a good buy. For example, gross profit margin measures Mangoceuticals, Common's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mangoceuticals, Common's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Mangoceuticals, Common's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mangoceuticals, Common Stock. Check Mangoceuticals, Common's Beneish M Score to see the likelihood of Mangoceuticals, Common's management manipulating its earnings.
Basic technical analysis of Mangoceuticals, Stock
As of the 27th of November, Mangoceuticals, Common secures the Standard Deviation of 6.16, mean deviation of 4.35, and Risk Adjusted Performance of (0.05). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mangoceuticals, Common, as well as the relationship between them.Mangoceuticals, Common's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mangoceuticals, Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mangoceuticals, Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mangoceuticals, Common insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Mangoceuticals, Common's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Mangoceuticals, Common's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (3.76) | |||
| Mean Deviation | 4.35 | |||
| Coefficient Of Variation | (1,227) | |||
| Standard Deviation | 6.16 | |||
| Variance | 38.0 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.53) | |||
| Total Risk Alpha | (1.48) | |||
| Treynor Ratio | (3.77) | |||
| Maximum Drawdown | 37.65 | |||
| Value At Risk | (10.11) | |||
| Potential Upside | 7.29 | |||
| Skewness | 1.2 | |||
| Kurtosis | 4.87 |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (3.76) | |||
| Mean Deviation | 4.35 | |||
| Coefficient Of Variation | (1,227) | |||
| Standard Deviation | 6.16 | |||
| Variance | 38.0 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.53) | |||
| Total Risk Alpha | (1.48) | |||
| Treynor Ratio | (3.77) | |||
| Maximum Drawdown | 37.65 | |||
| Value At Risk | (10.11) | |||
| Potential Upside | 7.29 | |||
| Skewness | 1.2 | |||
| Kurtosis | 4.87 |
Consider Mangoceuticals, Common's intraday indicators
Mangoceuticals, Common intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Mangoceuticals, Common stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Mangoceuticals, Common Corporate Filings
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 30th of August 2024 Other Reports | ViewVerify | |
F4 | 27th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Mangoceuticals, Stock media impact
Far too much social signal, news, headlines, and media speculation about Mangoceuticals, Common that are available to investors today. That information is available publicly through Mangoceuticals, media outlets and privately through word of mouth or via Mangoceuticals, internal channels. However, regardless of the origin, that massive amount of Mangoceuticals, data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Mangoceuticals, Common news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Mangoceuticals, Common relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Mangoceuticals, Common's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Mangoceuticals, Common alpha.
Mangoceuticals, Common Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Mangoceuticals, Common can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Additional Tools for Mangoceuticals, Stock Analysis
When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.